Erasca
Tracked across 3 events · 527 articles · First seen May 19, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Erasca is the defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about its drug candidate ERAS-0015, patent infringement claims, and a patient death during clinical trials. This has led to a significant drop in its stock price and market capitalization.
May 19, 2026 · 323 articles
Business
Impact: Erasca is the issuer of the proposed public offering, seeking to raise $500 million to fund its R&D programs. The dilution from the offering may negatively impact existing shareholders.
Jul 13, 2026 · 11 articles
Regulatory
A securities class action lawsuit has been filed against Erasca (NASDAQ: ERAS) alleging that the company and certain executives made false and misleading statements regarding its lead oncology candidate, ERAS-0015, a pan-RAS molecular glue. The…
Impact: Erasca is the defendant in the securities class action, accused of misleading investors about ERAS-0015. Its stock collapsed over 45% following disclosures of patent disputes and a patient death, erasing billions in market value.
Jun 11, 2026 · 193 articles
100
Robbins LLP filed class action lawsuit ErascaErasca Securities Fraud...
100
DJS Law Group filed class action ErascaErasca Securities Fraud...
100
Schall Brown & Schwartz LLP filed class action ErascaErasca Securities Fraud...
99
Levi & Korsinsky filed class action ErascaErasca Securities Fraud...
92
Erasca reported preliminary clinical dataErasca Securities Fraud...
90
Erasca disclosed patent challengeErasca Securities Fraud...
89
Erasca stock price fellErasca Securities Fraud...
88
Robbins Geller Rudman & Dowd LLP announced class action ErascaErasca Securities Fraud...
87
Revolution Medicines sent letter alleging infringement ErascaErasca Securities Fraud...
86
Kahn Swick & Foti notifies investors of lawsuit ErascaErasca Securities Fraud...
82
Rosen Law Firm announced class action lawsuit ErascaErasca Securities Fraud...
80
Erasca disclosed letterErasca Securities Fraud...
80
Erasca misrepresented preclinical data Revolution MedicinesErasca Securities Fraud...
80
Faruqi & Faruqi filed class action ErascaErasca Securities Fraud...
80
Kaplan Fox & Kilsheimer filed class action lawsuit ErascaErasca Securities Fraud...
79
The Law Offices of Frank R. Cruz filed securities fraud class action ErascaErasca Securities Fraud...
77
Hagens Berman filed class action ErascaErasca Securities Fraud...
75
Glancy Prongay & Murray filed class action lawsuit ErascaErasca Securities Fraud...
75
Berger Montague filed class action ErascaErasca Securities Fraud...
72
Pomerantz LLP filed class action lawsuit ErascaErasca Securities Fraud...
Revolution Medicines
patent defendant
↔
Erasca
Erasca is currently defending against a patent infringement and trade secret mis
Revolution Medicines
patent plaintiff
↔
Erasca
Revolution Medicines is actively pursuing a patent infringement and trade secret
ERGEN INTELLIGENCE
Track Erasca live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard